Before concluding his discussion on the management of B-cell malignancies, an expert shares insight on the ongoing challenges in this space.
Transcript
Michael A. Kolodziej, MD: So the biggest challenges I think that we will continue to face are that we have to make decisions based on incomplete data. As I said earlier, it is certainly true that our options are better than they used to be, but we still don’t know what the best option is. And we need to be sensitive to that when we’re counseling a patient about treatment options. I think we’re going to continue to be challenged by the cost. The cost is a huge issue: the cost to society, as well as the cost to the individual patient. And we have to come to grips with how we’re going to deal with that. And I’m not going to take a political stance on whether I like anything that the administration proposed or not, that doesn’t really make any difference. It’s just true that we’ve got to do something.
And then the last challenge I think is sometimes I get the impression that we fall into certain lanes because we have a target that we know works. And my friend, Peter Bach, MD, MAPP, has written extensively on this and I think he’s right. And Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence, has actually said this too, that we need to take chances, we need some real discovery. We need to come to grips with the idea that we’re going to actually cure certain malignancies or we’re going to treat them as chronic diseases. Either one is OK as far as I’m concerned. Each one has its relative advantages, obviously.
That we have a good option and maybe a better option is almost unfathomable because for years we had no good options. But I think we’re going to have to start sorting that out because it affects a lot about what our patients expect. It affects a lot about how much we’re willing to spend for this stuff.
Eliminating Enhanced PTCs Would Have Cascading Economic Impacts, Report Estimates
March 6th 2025Enhanced premium tax credits (PTCs) have made marketplace health insurance more affordable, and eliminating them could have sweeping impacts on consumers and the health care industry, according to a new report.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Potential Spillover Effects on Traditional Medicare When Physicians Bear Medicare Advantage Risk
February 26th 2025Medicare beneficiaries treated by physicians with high levels of Medicare Advantage risk exposure had higher care quality and efficiency outcomes compared with those treated by other physicians.
Read More